emcardioНеотложная кардиология и кардиоваскулярные рискиEmergency Cardiology and Cardiovascular Risks journal2616-633XБелорусский государственный медицинский университетemcardio-232Research ArticleОригинальные научные публикацииOriginal Scientific ResearchРезультаты факторного анализа маркеров лабораторной резистентности к ацетилсалициловой кислоте у пациентов со стабильной стенокардией напряженияResults of factor analysis of laboratory resistance markers to acetylsalicylic acid in patients with stable anginaПронькоТ. П.PronkoT. P.СнежицкийВ. А.SnezhitskiyV. A.ШуликаВ. Р.ShulikaV. R.УО «Гродненский государственный медицинский университет»Grodno State Medical University20191111202532713–718Copyright © Пронько Т.П., Снежицкий В.А., Шулика В.Р., 20252025Пронько Т.П., Снежицкий В.А., Шулика В.Р.Pronko T.P., Snezhitskiy V.A., Shulika V.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://emcardio.bsmu.by/jour/article/view/232

Цель исследования. Провести анализ маркеров, влияющих на развитие лабораторной резистентности к ацетилсалициловой кислоте (АСК) у пациентов со стабильной стенокардией напряжения.

The aim of the study was to assess the markers influencing the development of acetylsalicylic acid (ASA) laboratory resistance in patients with stable angina

аспиринорезистентностьстабильная стенокардия напряженияагрегация тромбоцитоввоспалениедисфункция эндотелияaspirin resistancestable anginaplatelet aggregationinflammationendothelial dysfunctionReferencesMichelson A.D., Cattaneo M., Eikelboom J.W. ., Gurbel P., Kottke-Marchant K., Kunicki T.J., Pulcinelli F.M., Cerletti C., Rao A.K. Aspirin Resistance: Position Paper of the Working Group on Aspirin Resistance, Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J. Thromb Haemost, 2005, vol. 3, no. 6, pp. 1309–1311.Michelson A.D., Cattaneo M., Eikelboom J.W. ., Gurbel P., Kottke-Marchant K., Kunicki T.J., Pulcinelli F.M., Cerletti C., Rao A.K. Aspirin Resistance: Position Paper of the Working Group on Aspirin Resistance, Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J. Thromb Haemost, 2005, vol. 3, no. 6, pp. 1309–1311.Snoep J.D., Hovens M.M., Eikenboom J.C., van der Bom J.G. Huisman M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and metaanalysis. Arch Intern Med, 2007, vol. 167, no. 15, pp. 1593–1599.Snoep J.D., Hovens M.M., Eikenboom J.C., van der Bom J.G. Huisman M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and metaanalysis. Arch Intern Med, 2007, vol. 167, no. 15, pp. 1593–1599.Puchin’yan N.F., Furman N.V., Dolotovskaya P.V., Malinova L.I. Vy’sokaya ostatochnaya reaktivnost’ trombocitov na fone dvoynoy antiagregantnoy terapii, vy’yavlennaya metodom opticheskoy agregometrii, i chastota razvitiya aterotromboticheskih oslojneniy posle stentirovaniya koronarny’h arteriy u bol’ny’h ishemicheskoy bolezn’yu serdca v real’noy klinicheskoy praktike [High residual platelet reactivity during dual antiplatelet therapy, detected by optical aggregometry, and the incidence of atherothrombotic complications after stenting of coronary arteries in patients with coronary heart disease in real clinical practice]. Ratsional’nya farmakoterapiya v kardiologii, 2016, vol. 12, no. 4, pp. 385–390. (in Russian).Puchin’yan N.F., Furman N.V., Dolotovskaya P.V., Malinova L.I. Vy’sokaya ostatochnaya reaktivnost’ trombocitov na fone dvoynoy antiagregantnoy terapii, vy’yavlennaya metodom opticheskoy agregometrii, i chastota razvitiya aterotromboticheskih oslojneniy posle stentirovaniya koronarny’h arteriy u bol’ny’h ishemicheskoy bolezn’yu serdca v real’noy klinicheskoy praktike [High residual platelet reactivity during dual antiplatelet therapy, detected by optical aggregometry, and the incidence of atherothrombotic complications after stenting of coronary arteries in patients with coronary heart disease in real clinical practice]. Ratsional’nya farmakoterapiya v kardiologii, 2016, vol. 12, no. 4, pp. 385–390. (in Russian).Pronko T.P., Snezhitskiy V.A., Makarova E.A, Avseenko A.A., Kharitonenko Т.V. Osobennosti trombocitarnogo gemostaza u pacientov s razlichnoj chuvstvitel’nost’yu k antitrombocitarnoj terapii pri stabil’noj stenokardii napryazheniya posle planovogo chreskozhnogo koronarnogo vmeshatel’stva [Features of platelet hemostasis in patients with various sensitivity to antiplatelet therapy in patients with angina pectoris in planned percutaneous coronary intervention]. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta, 2017, vol. 15, no 5, pp. 503–508. (in Russian).Pronko T.P., Snezhitskiy V.A., Makarova E.A, Avseenko A.A., Kharitonenko Т.V. Osobennosti trombocitarnogo gemostaza u pacientov s razlichnoj chuvstvitel’nost’yu k antitrombocitarnoj terapii pri stabil’noj stenokardii napryazheniya posle planovogo chreskozhnogo koronarnogo vmeshatel’stva [Features of platelet hemostasis in patients with various sensitivity to antiplatelet therapy in patients with angina pectoris in planned percutaneous coronary intervention]. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta, 2017, vol. 15, no 5, pp. 503–508. (in Russian).Wisman P.P., Roest M., Asselbergs F.W., de Groot P.G., Moll F.L., van der Graaf Y., de Borst G.J. Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis. J. Thromb. Haemost, 2014, vol. 12, no. 5, pp. 736–747.Wisman P.P., Roest M., Asselbergs F.W., de Groot P.G., Moll F.L., van der Graaf Y., de Borst G.J. Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis. J. Thromb. Haemost, 2014, vol. 12, no. 5, pp. 736–747.Kukula K., Klopotowski M., Kunicki P., Jamiolkowski J., Debski A., Bekta P., Chmielak Z., Witkowski A. Platelet aggregation and the risk of stent thrombosis or bleeding in elective percutaneous coronary intervention patients. Blood Coagul Fibrinolysis, 2017, vol. 28, no. 5, pp. 383–388. doi: 10.1097/MBC.0000000000000614.Kukula K., Klopotowski M., Kunicki P., Jamiolkowski J., Debski A., Bekta P., Chmielak Z., Witkowski A. Platelet aggregation and the risk of stent thrombosis or bleeding in elective percutaneous coronary intervention patients. Blood Coagul Fibrinolysis, 2017, vol. 28, no. 5, pp. 383–388. doi: 10.1097/MBC.0000000000000614.Würtz M. Aspirin in coronary artery disease: an appraisal of functions and limitations. Dan. Med. J, 2015, vol. 62, no. 4, pp. B5011.Würtz M. Aspirin in coronary artery disease: an appraisal of functions and limitations. Dan. Med. J, 2015, vol. 62, no. 4, pp. B5011.Gremmel T., Michelson A.D., Frelinger A.L., Bhatt D.L. Novel aspects of antiplatelet therapy in cardiovascular disease. Res. Pract. Thromb. Haemost, 2018, vol. 2, no. 3, pp. 439–449. doi: 10.1002/rth2.12115. eCollection 2018 Jul.Gremmel T., Michelson A.D., Frelinger A.L., Bhatt D.L. Novel aspects of antiplatelet therapy in cardiovascular disease. Res. Pract. Thromb. Haemost, 2018, vol. 2, no. 3, pp. 439–449. doi: 10.1002/rth2.12115. eCollection 2018 Jul.Martynov A.I., Akatova E.V., Urlayeva I.V., Nicolin O.P. True resistance and pseudoresistance to aspirin. Ration Pharmacother Cardiol, 2013, vol. 9, no 3, pp. 301–305.Martynov A.I., Akatova E.V., Urlayeva I.V., Nicolin O.P. True resistance and pseudoresistance to aspirin. Ration Pharmacother Cardiol, 2013, vol. 9, no 3, pp. 301–305.Lomakin N.V., Sumarokov A.B., Dotsenko Yu.V., Uchitel I.A., Buryachkovskaya L.I. Individual approach to patients with indication for antiplatelet therapy. What to rely on in choosing the therapy? [Individual approach to patients with indication for antiplatelet therapy. What to rely on in choosing the therapy?]. Aterotromboz, 2017, no. 2, pp. 70–80. (in Russian).Lomakin N.V., Sumarokov A.B., Dotsenko Yu.V., Uchitel I.A., Buryachkovskaya L.I. Individual approach to patients with indication for antiplatelet therapy. What to rely on in choosing the therapy? [Individual approach to patients with indication for antiplatelet therapy. What to rely on in choosing the therapy?]. Aterotromboz, 2017, no. 2, pp. 70–80. (in Russian).Calatzis A., Loreth R., Spannagl M. Multiplate® platelet function analysis - application and interpretation [electronic resource]. Available at: ttp://www.ecomeds.ru/data/files/catalog/1.%20Compendium%20Multiplate%20final%20V2.0_07.2007.pdf. (accessed 24.10.2019).Calatzis A., Loreth R., Spannagl M. Multiplate® platelet function analysis - application and interpretation [electronic resource]. Available at: ttp://www.ecomeds.ru/data/files/catalog/1.%20Compendium%20Multiplate%20final%20V2.0_07.2007.pdf. (accessed 24.10.2019).Bobescu E., Covaciu A., Rus H., Radoi M., Badea M., Moga S.N., Benza V, Marceanu L.G. Correlation of cardiovascular risk factors and biomarkers with platelet reactivity in coronary artery disease. Am. J. Ther, 2019, vol. 26, no. 5, pp. 563–569. doi: 10.1097/MJT.0000000000000869.Bobescu E., Covaciu A., Rus H., Radoi M., Badea M., Moga S.N., Benza V, Marceanu L.G. Correlation of cardiovascular risk factors and biomarkers with platelet reactivity in coronary artery disease. Am. J. Ther, 2019, vol. 26, no. 5, pp. 563–569. doi: 10.1097/MJT.0000000000000869.Larsen S.B., Grove E.L., Neergaard-Petersen S., Würtz M., Hvas A.M., Kristensen S.D. Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. PLoS One, 2015, vol. 10, no. 5, pp.e0126767. doi: 10.1371/journal.pone.0126767. eCollection 2015.Larsen S.B., Grove E.L., Neergaard-Petersen S., Würtz M., Hvas A.M., Kristensen S.D. Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease. PLoS One, 2015, vol. 10, no. 5, pp.e0126767. doi: 10.1371/journal.pone.0126767. eCollection 2015.Winter M.P., Schneeweiss T., Cremer R., Biesinger B., Hengstenberg C., Prüller F., Wallner M., Kolesnik E., von Lewinski D., Lang I.M., Siller-Matula J.M. Platelet reactivity patterns in patients treated with dual antiplatelet therapy. Eur J Clin Invest, 2019, vol. 49, no. 6, pp.e13102. doi: 10.1111/eci.13102.Winter M.P., Schneeweiss T., Cremer R., Biesinger B., Hengstenberg C., Prüller F., Wallner M., Kolesnik E., von Lewinski D., Lang I.M., Siller-Matula J.M. Platelet reactivity patterns in patients treated with dual antiplatelet therapy. Eur J Clin Invest, 2019, vol. 49, no. 6, pp.e13102. doi: 10.1111/eci.13102.Gelis L.G., Markova I.A., Medvedeva E.A., Shibeko N.A. Diagnosticheskaja rol trombocitov i plazmennyh faktorov krovi v razvitii aterotromboza [Diagnostic role of platelets and plasma blood factors in the development of atherothrombosis]. Kardiologija v Belarusi, 2012, no. 2, pp. 123–134. (in Russian).Gelis L.G., Markova I.A., Medvedeva E.A., Shibeko N.A. Diagnosticheskaja rol trombocitov i plazmennyh faktorov krovi v razvitii aterotromboza [Diagnostic role of platelets and plasma blood factors in the development of atherothrombosis]. Kardiologija v Belarusi, 2012, no. 2, pp. 123–134. (in Russian).Barinov Je. F., Gnilorybov A.M., Sulaeva O.N., Kanana N.N., Gatina E.I. Funkcionalnoe sostojanie trombocitov pri ishemicheskoj bolezni serdca [Functional state of thrombocytes in ischemic heart disease]. Vestnik neotlozhnoj i vosstanovitelnoj mediciny, 2013, vol. 14, no. 2, pp. 278–282. (in Russian).Barinov Je. F., Gnilorybov A.M., Sulaeva O.N., Kanana N.N., Gatina E.I. Funkcionalnoe sostojanie trombocitov pri ishemicheskoj bolezni serdca [Functional state of thrombocytes in ischemic heart disease]. Vestnik neotlozhnoj i vosstanovitelnoj mediciny, 2013, vol. 14, no. 2, pp. 278–282. (in Russian).Mazurov A.V. Oborot trombocitov i aterotromboz [The turnover of platelets, and atherothrombosis]. Aterotromboz, 2017, no. 2, pp. 131–141. (in Russian).Mazurov A.V. Oborot trombocitov i aterotromboz [The turnover of platelets, and atherothrombosis]. Aterotromboz, 2017, no. 2, pp. 131–141. (in Russian).Sansanayudh N., Anothaisintawee T., Muntham D., McEvoy M., Attia J., Thakkinstian A. Mean platelet volume and coronary artery disease: a systematic review and meta-analysis. Int. J. Cardiol, 2014, vol. 175, no. 3, pp. 433–440. doi: 10.1016/j.ijcard.2014.06.028.Sansanayudh N., Anothaisintawee T., Muntham D., McEvoy M., Attia J., Thakkinstian A. Mean platelet volume and coronary artery disease: a systematic review and meta-analysis. Int. J. Cardiol, 2014, vol. 175, no. 3, pp. 433–440. doi: 10.1016/j.ijcard.2014.06.028.Chu S.G., Becker R.C., Berger P.B., Bhatt D.L., Eikelboom J.W., Konkle B., Mohler E.R., Reilly M.P., Berger J.S. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J. Thromb. Haemost, 2010, vol. 8, no. 1, pp. 148–156.Chu S.G., Becker R.C., Berger P.B., Bhatt D.L., Eikelboom J.W., Konkle B., Mohler E.R., Reilly M.P., Berger J.S. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J. Thromb. Haemost, 2010, vol. 8, no. 1, pp. 148–156.Gromov A.A., Kruchinina M.V., Shvarts YA.SH., Kruchinin V.N., Rykhlitskiy S.V. Sistema gemostaza i aterogenez [Hemostasis system and atherogenesis]. Ateroskleroz, 2016, vol. 12, no. 2, pp. 39–60. (in Russian).Gromov A.A., Kruchinina M.V., Shvarts YA.SH., Kruchinin V.N., Rykhlitskiy S.V. Sistema gemostaza i aterogenez [Hemostasis system and atherogenesis]. Ateroskleroz, 2016, vol. 12, no. 2, pp. 39–60. (in Russian).Kruchinina M.V., Gromov A.A., Rabko A.V., Abdullayeva P.A., Baum V.A., Generalov V.M., Generalov K.V., Kruchinin V.N., Rykhlitskiy S.V., Shuvalov G.V. Aspirinorezis-tentnost’ kak marker riska venoznykh tromboembolicheskikh oslozhneniy [Aspirin resistance as a marker of risk of venous thromboembolic complications]. Ateroskleroz, 2018, vol. 14, no. 4, pp. 40–54. (in Russian).Kruchinina M.V., Gromov A.A., Rabko A.V., Abdullayeva P.A., Baum V.A., Generalov V.M., Generalov K.V., Kruchinin V.N., Rykhlitskiy S.V., Shuvalov G.V. Aspirinorezis-tentnost’ kak marker riska venoznykh tromboembolicheskikh oslozhneniy [Aspirin resistance as a marker of risk of venous thromboembolic complications]. Ateroskleroz, 2018, vol. 14, no. 4, pp. 40–54. (in Russian).Gimbrone M.A. Jr, García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ. Res, 2016, vol. 118, no. 4, pp. 620–636. doi: 10.1161/CIRCRESAHA.115.306301.Gimbrone M.A. Jr, García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ. Res, 2016, vol. 118, no. 4, pp. 620–636. doi: 10.1161/CIRCRESAHA.115.306301.Rajendran S., Chirkov Y.Y. Platelet hyperaggregability: impaired responsiveness to nitric oxide (“platelet NO resistance”) as a therapeutic target. Cardiovasc Drugs Ther, 2008, vol. 22, no. 3, pp. 193–203. doi: 10.1007/s10557-008-6098-7.Rajendran S., Chirkov Y.Y. Platelet hyperaggregability: impaired responsiveness to nitric oxide (“platelet NO resistance”) as a therapeutic target. Cardiovasc Drugs Ther, 2008, vol. 22, no. 3, pp. 193–203. doi: 10.1007/s10557-008-6098-7.Verigo YA.I., Demko I.V., Petrova M.M., Sobko Ye.A., Mamayeva M.G. Faktor Villenbranda i yego rol’ v disfunktsii endoteliya pri ishemicheskoy bolezni serdtsa [Willenbrand factor and its role in endothelial dysfunction in coronary heart disease]. Sibirskoye meditsinskoye obozreniye, 2014, no. 5, pp. 23–28. (in Russian).Verigo YA.I., Demko I.V., Petrova M.M., Sobko Ye.A., Mamayeva M.G. Faktor Villenbranda i yego rol’ v disfunktsii endoteliya pri ishemicheskoy bolezni serdtsa [Willenbrand factor and its role in endothelial dysfunction in coronary heart disease]. Sibirskoye meditsinskoye obozreniye, 2014, no. 5, pp. 23–28. (in Russian).Sokolov Ye.I., GrishinaT.I., Shtin S.R. Vliyaniye faktora Villebranda i endotelina-1 na formirovaniye tromboticheskogo statusa pri ishemicheskoy bolezni serdtsa [The effect of von Willebrand factor and endothelin-1 on the formation of thrombotic status in coronary heart disease]. Kardiologiya, 2013, no. 3, pp. 25–30. (in Russian).Sokolov Ye.I., GrishinaT.I., Shtin S.R. Vliyaniye faktora Villebranda i endotelina-1 na formirovaniye tromboticheskogo statusa pri ishemicheskoy bolezni serdtsa [The effect of von Willebrand factor and endothelin-1 on the formation of thrombotic status in coronary heart disease]. Kardiologiya, 2013, no. 3, pp. 25–30. (in Russian).

The authors declare that there are no conflicts of interest present.